Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6653869 | 1.00 | SIGMAR1 (0.42) | SIGMAR1STSOPRM1OPRD1GAA | |
| SCHEMBL6661553 | 0.86 | OPRM1 (0.34) | SIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL6661547 | 0.86 | OPRM1 (0.34) | SIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL6654085 | 0.84 | OPRM1 (0.41) | OPRM1OPRD1OPRK1 | |
| SCHEMBL6654080 | 0.84 | OPRM1 (0.41) | OPRM1OPRD1OPRK1 | |
| SCHEMBL6653130 | 0.83 | OPRM1 (0.52) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL6653132 | 0.83 | OPRM1 (0.52) | OPRM1OPRD1OPRK1KCNH2 | |
| Hydrochloric Acid SCHEMBL6657745 | 0.83 | OPRM1 (0.52) | OPRM1OPRD1OPRK1KCNH2 | |
| Hydrochloric Acid SCHEMBL6657743 | 0.83 | OPRM1 (0.52) | OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL7648038 | 0.82 | OPRM1 (0.53) | SIGMAR1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077940-B1 | 4-PHENYLPIPERIDINES FOR THE TREATMENT OF PRURITIC DERMATOSES | PFIZER (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6610711-B2 | 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | HRH2, HRH4, HRH1 | SIGMAR1 629/4885STS 4179/4885OPRM1 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.